Halozyme Therapeutics Inc (HALO) — Cash Flow Reinvestment Rate
Halozyme Therapeutics Inc (HALO) has a Cash Flow Reinvestment Rate of 1.15x as of September 2025, reinvesting $204.64 Million (capex $3.03 Million plus investments $201.61 Million) from operating cash flow of $178.60 Million. Explore reinvestment intensity of Halozyme Therapeutics Inc to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Halozyme Therapeutics Inc Cash Flow Reinvestment Rate (2006–2024)
Historical reinvestment intensity for Halozyme Therapeutics Inc across 7 annual periods. Also explore HALO current and non-current assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Halozyme Therapeutics Inc (2006–2024)
Year-by-year capital reinvestment analysis for Halozyme Therapeutics Inc. For live market cap and broader valuation context, see HALO market cap overview.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.57x | $273.42 Million | $479.06 Million | $10.70 Million | ▲ +97.7% |
| 2023 | 0.29x | $112.20 Million | $388.57 Million | $15.29 Million | ▼ -86.0% |
| 2022 | 2.06x | $495.73 Million | $240.11 Million | $4.81 Million | ▲ +52.2% |
| 2021 | 1.36x | $406.29 Million | $299.44 Million | $1.46 Million | ▼ -8.6% |
| 2020 | 1.48x | $82.29 Million | $55.45 Million | $2.50 Million | ▲ +20.5% |
| 2017 | 1.23x | $165.08 Million | $134.05 Million | $1.35 Million | ▲ +2289.9% |
| 2006 | 0.05x | $364.80K | $7.08 Million | $364.80K | — |